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EBV

:   Epstein‐Barr virus

EBVaGC

:   EBV‐associated GC

GC

:   gastric cancer

GS

:   genomically stable

MC

:   medullary carcinoma

MMR

:   mismatch repair

MSI

:   microsatellite instability

PDA

:   poorly differentiated adenocarcinoma

QMVR

:   quasimonomorphic variation range

TIL

:   tumor‐infiltrating lymphocyte

1. INTRODUCTION {#cas14301-sec-0001}
===============

Gastric cancer remains the third leading cause of cancer death worldwide. Although it is commonly supposed that PDA has a worse prognosis than other histological types, several studies showed that PDA with solid morphology is associated with a favorable prognosis despite its poorly differentiated histology.[1](#cas14301-bib-0001){ref-type="ref"}, [2](#cas14301-bib-0002){ref-type="ref"}, [3](#cas14301-bib-0003){ref-type="ref"}, [4](#cas14301-bib-0004){ref-type="ref"} According to the Japanese classification, PDAs are divided into the solid‐type and nonsolid‐type.[5](#cas14301-bib-0005){ref-type="ref"}

Solid‐type PDAs often contain a glandular component that tends to be detected superficially in the tumor, suggesting that solid‐type PDAs develop from a tubular or papillary adenocarcinoma.[6](#cas14301-bib-0006){ref-type="ref"} Previous studies reported that solid‐type PDA is associated with MSI,[6](#cas14301-bib-0006){ref-type="ref"}, [7](#cas14301-bib-0007){ref-type="ref"} which is caused by inactivation of MMR proteins such as MLH1, PMS2, MSH2, and MSH6.

A close relationship has been identified between MSI and ARID1A alteration in some neoplasms.[8](#cas14301-bib-0008){ref-type="ref"}, [9](#cas14301-bib-0009){ref-type="ref"}, [10](#cas14301-bib-0010){ref-type="ref"}, [11](#cas14301-bib-0011){ref-type="ref"}, [12](#cas14301-bib-0012){ref-type="ref"}, [13](#cas14301-bib-0013){ref-type="ref"}, [14](#cas14301-bib-0014){ref-type="ref"}, [15](#cas14301-bib-0015){ref-type="ref"} SWI/SNF family members such as ARID1A, INI1, BRG1, BRM, BAF155, and BAF170 are involved in the regulation of vital cellular processes, such as proliferation and differentiation, in a wide variety of neoplasms.[16](#cas14301-bib-0016){ref-type="ref"}, [17](#cas14301-bib-0017){ref-type="ref"}, [18](#cas14301-bib-0018){ref-type="ref"}, [19](#cas14301-bib-0019){ref-type="ref"} However, no analysis of the expression status of SWI/SNF family members in solid‐type PDAs has been undertaken to date.

In this study, we investigated the expression status of MMR proteins and SWI/SNF complex subunits by using samples from patients with solid‐type PDAs, and we compared the immunohistochemical status of the PDAs' glandular components and solid components. We undertook this investigation to elucidate the clinicopathological and molecular biological characteristics of solid‐type PDAs of the stomach.

2. MATERIALS AND METHODS {#cas14301-sec-0002}
========================

2.1. Case selection {#cas14301-sec-0003}
-------------------

A total of 1810 cases of GC were resected at Kyushu University Hospital (Fukuoka, Japan) and affiliated hospitals from 2006 to 2012. Using the surgical pathology files of Kyushu University Hospital, we collected 54 GC cases (54/1810, 3.0%) diagnosed as solid‐type PDA. According to the Japanese Classification of Gastric Carcinoma,[5](#cas14301-bib-0005){ref-type="ref"} solid‐type PDA shows a sheet‐like solid growth pattern with scanty stroma (Figure [1](#cas14301-fig-0001){ref-type="fig"}). Special histological types such as lymphoepithelioma‐like carcinomas, neuroendocrine carcinoma, and hepatoid adenocarcinoma were excluded. Additionally, we selected 40 cases of stage‐matched GC without solid‐type PDA as a control group, whose time of receiving gastrectomy was close to that of the solid‐type PDA groups. All patients were staged according to the 8th edition of the UICC TNM classification. In a control group, 25 of 40 cases were tubular adenocarcinomas, and 15 of 40 cases were nonsolid‐type PDAs or signet‐ring cell carcinomas. None of cases received preoperative chemotherapy except for 1 case of solid‐type PDA. All of the patients had undergone curative resection. The research protocol was approved by the Kyushu University Medical Human Investigation Committee (Institutional Review Board no. 29‐240).

![Solid‐type poorly differentiated adenocarcinoma showing an expansive growth pattern at the periphery. High‐magnification image (200×) showing tumor‐infiltrating lymphocytes and tumor cells with vesicular nuclei and prominent nucleoli](CAS-111-1008-g001){#cas14301-fig-0001}

2.2. Clinicopathological assessment {#cas14301-sec-0004}
-----------------------------------

We analyzed the clinical characteristics of all cases, including patient age, sex, tumor location, tumor size, growth pattern, lymphatic and venous invasion, coexisting glandular component, TILs, Crohn's‐like reaction, and the UICC TNM stage. Tumor‐infiltrating lymphocytes and Crohn's‐like reaction were evaluated as described.[20](#cas14301-bib-0020){ref-type="ref"}, [21](#cas14301-bib-0021){ref-type="ref"}

2.3. Immunohistochemistry {#cas14301-sec-0005}
-------------------------

We undertook immunohistochemical staining using the universal immunoperoxidase polymer method (EnVision Kit; Dako) or the streptavidin‐biotin‐peroxidase method (Histofine) for all available cases. Formalin‐fixed, paraffin‐embedded tissues were sectioned at 4 μm. Antigen retrieval was carried out by boiling the slides with 10 mM sodium citrate (pH 6.0) or Target Retrieval Solution (Dako). The primary Abs and staining conditions are summarized in Table [1](#cas14301-tbl-0001){ref-type="table"}.

###### 

Primary Abs used for immunohistochemical staining

  Antibody         Clone        Company                    Dilution
  ---------------- ------------ -------------------------- ----------
  MLH1             G168‐15      BD Bioscience              1:50
  PMS2             A16‐4        BD Bioscience              1:200
  MSH2             Ab‐2         Calbiochem                 1:100
  MSH6             EP49         Dako                       1:200
  ARID1A           Polyclonal   SIGMA                      1:500
  SMARCB1/INI1     25/BAF47     BD Bioscience              1:250
  SMARCA4/BRG1     G‐7          Santa Cruz Biotechnology   1:25
  SMARCA2/BRM      Polyclonal   Abcam                      1:50
  SMARCC1/BAF155   DXD7         Santa Cruz Biotechnology   1:50
  SMARCC2/BAF170   E‐6          Santa Cruz Biotechnology   1:100
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The expressions of MMR proteins (MLH1, PMS2, MSH2, and MSH6) were judged as "loss" when there was a complete absence of nuclear staining in neoplastic cells, while the surrounding nonneoplastic cells showed consistently preserved nuclear staining.

In our assessment of ARID1A, INI1, BRM, BRG1, BAF155, and BAF170, only unequivocally clearly absent staining in the nuclei of viable tumor tissue (away from necrotic areas) was considered "loss." As a control, the presence of homogenous strong nuclear staining of stromal fibroblasts, inflammatory cells, vascular endothelial cells, or normal epithelial cells in the background was a prerequisite for assessable staining in the tumor. Staining proportion was graded as complete loss (0%‐4%), partial loss (5%‐49%), or retained (50%‐100%) based on a described labeling index.[22](#cas14301-bib-0022){ref-type="ref"}

2.4. In situ hybridization of EBV‐encoded small RNA (EBER) {#cas14301-sec-0006}
----------------------------------------------------------

To examine the EBV infection status, we stained 3‐μm‐thick sections for in situ hybridization. EBER probe (\#Y5200; Dako) was detected using the PNA ISH Detection Kit (\#K5201; Dako). Identifiable nuclear staining for EBER was interpreted as a positive result.

2.5. Mutational analysis {#cas14301-sec-0007}
------------------------

We carried out PCR and a Sanger sequencing analysis to detect gene mutations in *KRAS* codons 12 and 13, and *BRAF* (V600E). Genomic DNA was extracted from paraffin‐embedded tissue using a QIAamp DNA FFPE Tissue Kit (Qiagen) according to the manufacturer's instructions. The PCR conditions and primer sequences as well as the Sanger sequence procedures were as described.[23](#cas14301-bib-0023){ref-type="ref"} If the quality of the DNA or the level of PCR amplification in a patient's case was insufficient for a mutation analysis, the case was excluded from the molecular study.

2.6. Microsatellite instability analysis {#cas14301-sec-0008}
----------------------------------------

Microsatellite instability analysis was carried out by using an MSI Analysis Kit (FALCO) (FALCO Biosystems) with the 5 microsatellite markers BAT‐26, NR‐21, BAT‐25, MONO‐27, and NR‐24, according to the QMVR method without paired normal DNA reported previously.[24](#cas14301-bib-0024){ref-type="ref"} The PCR was carried out using the Veriti thermal cycler (Life Technologies), and PCR amplicon was diluted by distilled water and applied to a 3130xl Genetic Analyzer (Life Technologies). Fragment analysis was undertaken by GeneMapper software (Life Technologies). Tumors showing markers outside the corresponding QMVR were defined as MSI. We classified the tumors as MSI‐High if 2 or more of the 5 markers showed MSI, and negative (MSI‐Low or MSS) if one marker or less showed MSI.

2.7. Statistical analysis {#cas14301-sec-0009}
-------------------------

We assessed statistical differences between the groups using the Mann‐Whitney *U* test, the χ^2^ test, or Fisher's exact test. Survival data were assessed by the Kaplan‐Meier method and tested for significance between the groups with the log‐rank test. All calculations were undertaken using JMP software version 13.0 (SAS Institute). *P* values less than .05 were considered significant.

3. RESULTS {#cas14301-sec-0010}
==========

3.1. Clinicopathological status, immunohistochemistry, and in situ hybridization {#cas14301-sec-0011}
--------------------------------------------------------------------------------

The clinicopathological features and results of immunohistochemistry and in situ hybridization are summarized in Tables [2](#cas14301-tbl-0002){ref-type="table"} and [3](#cas14301-tbl-0003){ref-type="table"}, and representative immunohistochemical images are provided in Figure [2](#cas14301-fig-0002){ref-type="fig"}. Of the patients with solid‐type PDAs, 35 were men and 19 were women, with a median age of 74.5 years (range, 55‐90 years). Solid‐type PDAs showed frequent expansive growth patterns (52%), TILs (57%), Crohn's‐like reaction (33%), and coexisting glandular component (76%). Mismatch repair deficiency was seen in 21 of the 54 tumors (39%). All of the MMR‐deficient tumors showed a concurrent loss of MLH1/PMS2, and none of the cases showed other patterns of MMR deficiency. EBER positivity was found in 2 of the 54 cases (4%). The features of both EBER‐positive tumors were male sex, TILs, upper‐third location, and MMR proficient.

###### 

Clinicopathologic status of solid‐type poorly differentiated adenocarcinomas (PDAs) and gastric cancers in the control group

                                       Solid‐type PDAs   Control group   *P* value                                        MMR‐deficient   MMR‐proficient   *P* value
  ------------------------------------ ----------------- --------------- ------------------------------------------------ --------------- ---------------- ------------------------------------------------
  Age, y; median (range)               74.5 (55‐90)      69 (53‐84)      .0026[\*](#cas14301-note-0003){ref-type="fn"}    77 (62‐90)      73 (55‐87)       .1288
  Male, n (%)                          35 (65)           34 (85)         .0285[\*](#cas14301-note-0003){ref-type="fn"}    9 (43)          26 (79)          .007[\*](#cas14301-note-0003){ref-type="fn"}
  Female, n (%)                        19 (35)           4 (15)          12 (57)                                          7 (21)                           
  Location, n (%)                                                                                                                                          
  U                                    10 (19)           14 (35)         .0128[\*](#cas14301-note-0003){ref-type="fn"}    2 (10)          8 (24)           .0038[\*](#cas14301-note-0003){ref-type="fn"}
  M                                    23 (43)           21 (53)         5 (24)                                           18 (55)                          
  L                                    21 (39)           5 (13)          14 (67)                                          7 (21)                           
  Size, mm; median (range)             72 (12‐170)       44 (15‐140)     .0002[\*](#cas14301-note-0003){ref-type="fn"}    74 (18‐140)     70 (12‐170)      .8521
  Growth pattern, n (%)                                                                                                                                    
  Expansile                            28 (52)           4 (10)          \<.001[\*](#cas14301-note-0003){ref-type="fn"}   16 (76)         12 (36)          .0043[\*](#cas14301-note-0003){ref-type="fn"}
  Infiltrative                         26 (48)           36 (90)         5 (24)                                           21 (64)                          
  Lymphatic invasion (+)               33 (61)           20 (50)         .2828                                            14 (67)         19 (58)          .5041
  Venous invasion (+)                  29 (54)           16 (40)         .1885                                            8 (38)          21 (64)          .0665
  Tumor‐infiltrating lymphocytes (+)   31 (57)           4 (10)          \<.001[\*](#cas14301-note-0003){ref-type="fn"}   21 (100)        10 (30)          \<.001[\*](#cas14301-note-0003){ref-type="fn"}
  Crohn\'s‐like reaction (+)           18 (33)           6 (15)          .0439                                            12 (57)         6 (18)           .0031[\*](#cas14301-note-0003){ref-type="fn"}
  Glandular component (+)              41 (76)           30 (75)         .9178                                            18 (86)         23 (70)          .1796
  pT stage, n (%)                                                                                                                                          
  pT1b‐2                               15 (28)           16 (40)         .2127                                            7 (33)          8 (24)           .4672
  pT3‐4                                39 (72)           24 (60)         14 (67)                                          25 (76)                          
  pN stage, n (%)                                                                                                                                          
  pN0                                  20 (37)           10 (25)         .2158                                            7 (33)          13 (39)          .653
  pN1‐3                                34 (63)           30 (75)         14 (67)                                          20 (61)                          
  pM stage, n (%)                                                                                                                                          
  M0                                   53 (98)           39 (98)         .8295                                            21 (100)        32 (97)          .4207
  M1                                   1 (2)             1 (3)           0 (0)                                            1 (3)                            
  pStage, n (%)                                                                                                                                            
  I                                    12 (22)           9 (23)          .997                                             6 (29)          6 (18)           .6836
  II                                   18 (33)           13 (33)         6 (29)                                           12 (36)                          
  III                                  23 (43)           17 (43)         9 (43)                                           14 (42)                          
  IV                                   1 (2)             1 (3)           0 (0)                                            1 (3)                            

Data were analyzed using the χ^2^ test, except for age and size, which were analyzed using the Mann‐Whitney *U* test.

Abbreviations: L, lower third location; M, middle third location; MMR, mismatch repair; U, upper third location.

Statistically significant.
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###### 

Immunohistochemistry and in situ hybridization of solid‐type poorly differentiated adenocarcinomas (PDAs) and gastric cancers in the control group

                    Solid‐type PDAs   Control group   *P* value                                         MMR‐deficient   MMR‐proficient   *P* value
  ----------------- ----------------- --------------- ------------------------------------------------- --------------- ---------------- ------------------------------------------------
  Mismatch repair                                                                                                                        
  Deficient         21 (39)           2 (5)           .0002[\*](#cas14301-note-0006){ref-type="fn"}                                       
  Proficient        33 (61)           38 (95)                                                                                             
  EBER‐ISH                                                                                                                               
  Positive          2 (4)             2 (5)           .7582                                             0 (0)           2 (6)            .2503
  Negative          52 (96)           38 (95)         21 (100)                                          31 (94)                          
  ARID1A                                                                                                                                 
  Complete loss     17 (31)           4 (10)          .0057[\*](#cas14301-note-0006){ref-type="fn"}     14 (67)         3 (9)            \<.001[\*](#cas14301-note-0006){ref-type="fn"}
  Partial loss      4 (7)             0 (0)           2 (10)                                            2 (6)                            
  Retained          33 (61)           36 (90)         5 (24)                                            28 (85)                          
  INI1                                                                                                                                   
  Complete loss     2 (4)             0 0)            .2128                                             1 (5)           1 (3)            .1807
  Partial loss      2 (4)             0 0)            2 (10)                                            0 (0)                            
  Retained          50 (93)           40 (100)        18 (86)                                           32 (97)                          
  BRG1                                                                                                                                   
  Complete loss     26 (48)           2 (5)           \<.001[\*](#cas14301-note-0006){ref-type="fn"}    13 (62)         13 (40)          .0445[\*](#cas14301-note-0006){ref-type="fn"}
  Partial loss      16 (30)           8 (20)          7 (33)                                            9 (27)                           
  Retained          12 (22)           30 (75)         1 (5)                                             11 (33)                          
  BRM                                                                                                                                    
  Complete loss     18 (33)           3 (8)           \<.0005[\*](#cas14301-note-0006){ref-type="fn"}   7 (33)          11 (33)          .7915
  Partial loss      18 (33)           8 (20)          8 (38)                                            10 (30)                          
  Retained          18 (33)           29 (73)         6 (29)                                            12 (36)                          
  BAF155                                                                                                                                 
  Complete loss     7 (13)            5 (13)          .0003[\*](#cas14301-note-0006){ref-type="fn"}     6 (29)          1 (3)            \<.001[\*](#cas14301-note-0006){ref-type="fn"}
  Partial loss      22 (41)           2 (5)           12 (57)                                           10 (30)                          
  Retained          25 (46)           33 (83)         3 (14)                                            22 (67)                          
  BAF170                                                                                                                                 
  Complete loss     3 (6)             0 (0)           .2128                                             3 (14)          0 (0)            .0631
  Partial loss      1 (2)             0 (0)           0 (0)                                             1 (3)                            
  Retained          50 (93)           40 (100)        18 (86)                                           32 (97)                          

Data were analyzed using the χ^2^ test, except for age and size, which were analyzed using the Mann‐Whitney *U*test.

Abbreviations: ISH, in situ hybridization; MMR, mismatch repair.

Statistically significant.

John Wiley & Sons, Ltd

![Representative immunohistochemical images of ARID1A (A, B), BRG1 (C, D), BRM (E, F), INI1 (G, H), BAF155 (I, J), and BAF170 (K, L) in solid‐type poorly differentiated adenocarcinomas. Note the retained expressions of ARID1A (A), BRG1 (C), BRM (E), INI1 (G), BAF155 (I), and BAF170 (K). Note the loss of expression of ARID1A (B), BRG1 (D), BRM (F), INI1 (H), BAF155 (J), and BAF170 (L), whereas lymphocytes, fibrocytes, and vascular endothelial cells show retained expression of SWI/SWF subunits](CAS-111-1008-g002){#cas14301-fig-0002}

Solid components in solid‐type PDAs are usually seen at the invasive area, whereas glandular components are seen at the superficial area. We evaluated the immunohistochemical status of solid components in solid‐type PDAs and invasive areas of GC in the control group. The solid‐type PDAs showed a complete/partial loss of ARID1A (31%/7%), INI1 (4%/4%), BRG1 (48%/30%), BRM (33%/33%), BAF155 (13%/41%), and BAF170 (6%/2%). Compared to the control group, solid‐type PDAs were associated with lower third location (*P* = .0128), larger size (*P* = .0002), expansive growth pattern (*P* \< .001), TILs (*P* \< .001), Crohn's‐like reaction (*P* = .0439), MMR deficiency (*P* = .0002), and loss of ARID1A, BRG1, BRM, and BAF155 (*P* = .0057, *P* \< .001, *P* = .0005, and *P* = .0003, respectively). In the control group, 15 cases of nonsolid‐type PDA or signet‐ring cell carcinoma showed a complete/partial loss of ARID1A (20%/0%), INI1 (0%/0%), BRG1 (0%/20%), BRM (7%/13%), BAF155 (20%/13%), and BAF170 (0%/0%), and 25 cases of tubular adenocarcinoma showed a complete/partial loss of ARID1A (4%/0%), INI1 (0%/0%), BRG1 (8%/20%), BRM (8%/24%), BAF155 (8%/0%), and BAF170 (0%/0%).

Our comparison of the MMR‐deficient and MMR‐proficient groups revealed that the patients in the MMR‐deficient group were relatively older than those in the MMR‐proficient group (*P* = .1288). Mismatch repair deficiency was associated with female sex, lower third location, expansive growth pattern, TILs, and Crohn's‐like reaction (*P* = .007, *P* = .0038, *P* = .0043, *P* \< .001, and *P* = .0031, respectively). The MMR‐deficient group showed significantly more frequent losses of ARID1A, BRG1, and BAF155 than the MMR‐proficient group (*P* \< .001, *P* = .0445, and *P* \< .001, respectively). The MMR‐deficient group showed more frequent losses of INI1, BRM, and BAF170 compared to the MMR‐proficient group, but the differences were not significant (*P* = .1807, *P* = .7915, and *P* = .0631, respectively). All 21 of the MMR‐deficient solid‐type PDAs (100%) and 30 of the 33 MMR‐proficient solid‐type PDAs (91%) showed a complete or partial loss of at least 1 of the SWI/SNF complex subunits.

3.2. Comparison of glandular and solid components: Immunohistochemical status of SWI/SNF complex components {#cas14301-sec-0012}
-----------------------------------------------------------------------------------------------------------

Glandular components were seen in 18 of the 21 MMR‐deficient tumors (86%) and 23 of the 33 MMR‐proficient tumors (70%). We compared the immunohistochemical status of the glandular and solid components and observed that the expression pattern of MMR proteins was the same in both glandular and solid components in all cases. The features of the solid‐type PDAs with glandular component are summarized in Table [4](#cas14301-tbl-0004){ref-type="table"}, and an example is presented in Figure [3](#cas14301-fig-0003){ref-type="fig"}. Loss of SWI/SNF family members was observed more frequently in solid components compared to the glandular components in both the MMR‐deficient and ‐proficient groups.

###### 

Comparison of immunohistochemical status between glandular and solid components

                  MMR‐deficient group (n = 18)   MMR‐proficient group (n = 23)                                                                       
  --------------- ------------------------------ ------------------------------- ----------------------------------------------- --------- --------- ----------------------------------------------
  ARID1A                                                                                                                                             
  Complete loss   4 (22)                         12 (67)                         .0268[\*](#cas14301-note-0009){ref-type="fn"}   2 (9)     3 (13)    .2966
  Partial loss    4 (22)                         2 (11)                          0 (0)                                           2 (9)               
  Retained        10 (56)                        4 (22)                          21 (91)                                         18 (78)             
  INI1                                                                                                                                               
  Complete loss   1 (6)                          1 (6)                           .3456                                           0 (0)     1 (4)     .312
  Partial loss    0 (0)                          2 (11)                          0 (0)                                           0 (0)               
  Retained        17 (94)                        15 (83)                         23 (100)                                        22 (96)             
  BRG1                                                                                                                                               
  Complete loss   6 (33)                         13 (72)                         .0181[\*](#cas14301-note-0009){ref-type="fn"}   5 (22)    11 (48)   .012[\*](#cas14301-note-0009){ref-type="fn"}
  Partial loss    4 (22)                         4 (22)                          3 (13)                                          7 (30)              
  Retained        8 (44)                         1 (6)                           15 (65)                                         5 (22)              
  BRM                                                                                                                                                
  Complete loss   4 (22)                         7 (39)                          .0224[\*](#cas14301-note-0009){ref-type="fn"}   6 (26)    9 (39)    .3248
  Partial loss    2 (11)                         7 (39)                          5 (22)                                          7 (30)              
  Retained        12 (67)                        4 (22)                          12 (52)                                         7 (30)              
  BAF155                                                                                                                                             
  Complete loss   2 (11)                         6 (33)                          .0071[\*](#cas14301-note-0009){ref-type="fn"}   0 (0)     0 (0)     .3454
  Partial loss    5 (28)                         10 (56)                         6 (26)                                          9 (39)              
  Retained        11 (61)                        4 (22)                          17 (74)                                         14 (61)             
  BAF170                                                                                                                                             
  Complete loss   2 (11)                         3 (17)                          .6299                                           0 (0)     0 (0)     .321
  Partial loss    0 (0)                          0 (0)                           0 (0)                                           1 (4)               
  Retained        16 (89)                        15 (83)                         23 (100)                                        22 (96)             

Data were analyzed using the χ^2^ test.

Abbreviation: MMR, mismatch repair.

Statistically significant.
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![A, Mismatch repair‐deficient solid‐type poorly differentiated adenocarcinoma with a glandular component at the superficial area. B, C, Both the glandular and solid components showed MLH1 loss. D, E, Only the solid component showed a complete loss of ARID1A](CAS-111-1008-g003){#cas14301-fig-0003}

In the MMR‐deficient group, the differences in the expression status of ARID1A, BRG1, BRM, and BAF155 between the 2 types of components were significant (*P* = .0268, *P* = .0181, *P* = .0224, and *P* = .0071, respectively), but the differences in the expression status of INI1 and BAF170 did not reach significance (*P* = .3456 and *P* = .6299, respectively). In the MMR‐proficient group, the difference in the expression status of BRG1 was significant (*P* = .012), but the differences in the expression status of ARID1A, INI1, BRM, BAF155, and BAF170 did not reach significance (*P* = .2966, *P* = .312, *P* = .3248, *P* = .3454, and *P* = .321, respectively).

3.3. Molecular features {#cas14301-sec-0013}
-----------------------

We analyzed the mutational status of *KRAS* and *BRAF* in solid‐type PDAs. The results of the mutational analysis are summarized in Table [5](#cas14301-tbl-0005){ref-type="table"}. We excluded 13 and 12 tumors from the *KRAS* and *BRAF* mutational analyses, respectively, because of an insufficient quality of DNA or level of PCR amplification. *KRAS* mutations at codon 12 (GGT to GAT \[Gly to Asp\]) were observed in 2 solid‐type PDA cases, and *BRAF* mutation at codon 600 of exon 15 (GTG to GAG \[Val to Glu\]) was observed in 1 solid‐type PDA case.

###### 

Result of mutational analysis in solid‐type poorly differentiated adenocarcinomas

                              All cases   MMR‐deficient   MMR‐proficient   *P* value
  --------------------------- ----------- --------------- ---------------- -----------
  *KRAS* (codons 12 and 13)                                                
  Wild‐type                   39 (95)     13 (93)         26 (96)          .1597
  Mutant‐type                 2 (5)       1 (7)           1 (4)            
  Unknown                     13          7               6                
  *BRAF* (V600)                                                            
  Wild‐type                   41 (98)     15 (94)         26 (100)         .1970
  Mutant‐type                 1 (2)       1 (6)           0 (0)            
  Unknown                     12          5               7                

Data were analyzed using the χ^2^ test.

Abbreviation: MMR, mismatch repair.

John Wiley & Sons, Ltd

We analyzed the MSI status of 21 MMR‐deficient solid‐type PDAs to validate the immunohistochemistry of MMR proteins. We excluded 8 tumors because of insufficient quality of DNA or level of PCR amplification. The MSI analysis revealed that all 13 MMR‐deficient solid‐type PDAs were MSI‐High.

3.4. Prognosis after surgery {#cas14301-sec-0014}
----------------------------

The Kaplan‐Meier curves illustrating the comparison of solid‐type PDAs and GC in the control group, and the association of immunohistochemical status with survival in the solid‐type PDA patients are shown in Figure [4](#cas14301-fig-0004){ref-type="fig"}. There was no significant difference between the solid‐type PDAs and GC in the control group (*P* = .4282). In the solid‐type PDAs, the MMR‐deficient group showed relatively longer overall survival than the MMR‐proficient group, but the difference did not reach significance (*P* = .1125). The ARID1A complete/partial loss group showed significantly longer overall survival than the ARID1A retained group (*P* = .0203). There were no significant correlations between other SWI/SNF subunits and prognosis in solid‐type PDAs. As for TNM stage, there were no significant correlations between the expression status of each SWI/SNF complex subunit (retained vs complete/partial loss) and cancer depth (pT1b‐2 vs pT3‐4) or cancer stage (pStage I/II vs pStage III/IV) (Table [6](#cas14301-tbl-0006){ref-type="table"}).

![Kaplan‐Meier curves illustrating the comparison of solid‐type poorly differentiated adenocarcinomas (PDAs) and gastric cancers in the control group, and the association of immunohistochemical status with survival in solid‐type PDA patients. There was no significant difference between the solid‐type PDAs and gastric cancers in the control group (*P* = .4282). In the solid‐type PDAs, the mismatch repair (MMR)‐deficient group showed relatively longer overall survival than the MMR‐proficient group (*P* = .1125). The ARID1A complete/partial loss group showed significantly longer overall survival than the ARID1A retained group (*P* = .0203). There were no significant correlations between other SWI/SNF subunits and prognosis in solid‐type PDAs](CAS-111-1008-g004){#cas14301-fig-0004}

###### 

Relationship between immunohistochemical status and TNM stage in solid‐type poorly differentiated adenocarcinomas

                          pT stage   pStage                                   
  ----------------------- ---------- --------- --------- ---------- --------- -------
  ARID1A                                                                      
  Complete/partial loss   8 (53)     13 (33)   .1769     12 (40)    9 (38)    .8515
  Retained                7 (47)     26 (67)   18 (60)   15 (63)              
  INI1                                                                        
  Complete/partial loss   1 (7)      3 (8)     .8974     4 (13)     0 (0)     .063
  Retained                14 (93)    36 (92)   26(87)    24 (100)             
  BRG1                                                                        
  Complete/partial loss   11 (73)    31 (79)   .6261     24 (80)    18 (75)   .6605
  Retained                4 (27)     8 (21)    6 (20)    6 (25)               
  BRM                                                                         
  Complete/partial loss   11 (73)    25 (64)   .5192     20 (67)    16 (67)   1.0
  Retained                4 (27)     14 (36)   10 (33)   8 (33)               
  BAF155                                                                      
  Complete/partial loss   10 (67)    19 (49)   .2361     18 (60)    11 (46)   .2995
  Retained                5 (33)     20 (51)   12 (40)   13 (54)              
  BAF170                                                                      
  Complete/partial loss   3 (20)     1 (3)     .0604     4 (13)     0 (0)     .063
  Retained                12 (80)    38 (97)   26 (87)   24 (100)             

Data were analyzed using the χ^2^ test.
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4. DISCUSSION {#cas14301-sec-0015}
=============

We expanded our understanding of the clinicopathological and molecular features of gastric solid‐type PDA in the present study. Mismatch repair deficiency was seen in 21 of 54 cases (39%), and all of them showed a concurrent loss of the MLH1/PMS2 pattern. Arai et al reported that the proportion of MSI in solid‐type PDA was 43.0%‐51.6%,[6](#cas14301-bib-0006){ref-type="ref"}, [7](#cas14301-bib-0007){ref-type="ref"} which is similar to our present finding. Other studies showed MLH1 loss in GC (16%‐19%), complete or partial loss of ARID1A in GC (11%‐19%), and complete or partial loss of ARID1A in GC with MLH1 loss (29%‐33%).[10](#cas14301-bib-0010){ref-type="ref"}, [11](#cas14301-bib-0011){ref-type="ref"} Our present analyses revealed much more frequent MMR deficiency in solid‐type PDAs (21/54, 39%), complete or partial loss of ARID1A in solid‐type PDAs (21/54, 39%), and complete or partial loss of ARID1A in MMR‐deficient solid‐type PDAs (76%) compared to other histological types of GC in previous studies and the present study.

The solid‐type PDAs often contained a glandular component at the superficial area in both the MMR‐deficient group (18/21, 86%) and MMR‐proficient group (23/33, 70%), suggesting that most solid‐type PDAs developed from differentiated‐type adenocarcinomas such as tubular or papillary adenocarcinomas. We observed the loss of SWI/SNF members more frequently in solid components compared to glandular components in MMR‐deficient and MMR‐proficient groups. In the present study, all 21 of the MMR‐deficient solid‐type PDAs (100%) and 30 of the 33 MMR‐proficient solid‐type PDAs (91%) showed a complete or partial loss of at least 1 of the SWI/SNF complex subunits. Several studies indicated that the loss of ARID1A or INI1 was associated with medullary morphology in colorectal cancer,[13](#cas14301-bib-0013){ref-type="ref"}, [14](#cas14301-bib-0014){ref-type="ref"}, [25](#cas14301-bib-0025){ref-type="ref"}, [26](#cas14301-bib-0026){ref-type="ref"} and that the loss of BRG1 or BRM was associated with solid morphology in lung cancer.[27](#cas14301-bib-0027){ref-type="ref"} Our present findings suggest that the loss of the SWI/SNF complex plays a role in a morphological shift from glandular to solid component as a second hit rather than carcinogenesis.

It was reported that the loss of BRM or ARID1A in GC was associated with poorly differentiated histology.[11](#cas14301-bib-0011){ref-type="ref"}, [28](#cas14301-bib-0028){ref-type="ref"} Yan et al reported that ARID1A knockdown in GC cell lines induced a downregulation of E‐cadherin transcription and morphological changes of GC cells with increased expressions of mesenchymal markers.[29](#cas14301-bib-0029){ref-type="ref"} Banine et al[30](#cas14301-bib-0030){ref-type="ref"} suggested that the loss of SWI/SNF family members such as BRG1 or BRM induces E‐cadherin promoter methylation. These mechanisms could be related to a morphological shift in GC.

The overwhelming majority of GCs are associated with chronic gastritis by *Helicobacter pylori* infection.[31](#cas14301-bib-0031){ref-type="ref"} Chronic gastritis induces MLH1 promoter methylation,[32](#cas14301-bib-0032){ref-type="ref"} which leads to loss of MLH1 protein and MSI status. In our comparison of the MMR‐deficient and MMR‐proficient groups, we found that female sex, lower third location, expansive growth pattern, TILs, Crohn's‐like reaction, and loss of ARID1A, BRG1, and BAF155 were more frequently present in the MMR‐deficient group compared to the MMR‐proficient group. The features of the MMR‐deficient solid‐type PDAs are similar to those of colorectal MC, which is associated with female sex, right‐side colon, TILs, Crohn's‐like reaction, MSI, favorable prognosis, and ARID1A loss.[24](#cas14301-bib-0024){ref-type="ref"}, [33](#cas14301-bib-0033){ref-type="ref"}, [34](#cas14301-bib-0034){ref-type="ref"}, [35](#cas14301-bib-0035){ref-type="ref"}, [36](#cas14301-bib-0036){ref-type="ref"}, [37](#cas14301-bib-0037){ref-type="ref"} These similarities suggest that MMR‐deficient solid‐type PDA is a gastric counterpart of colorectal MC, as illustrated in Figure [5](#cas14301-fig-0005){ref-type="fig"}.

![Schematic representation of the hypothetical roles of mismatch repair (MMR) and SWI/SNF complex in gastric solid‐type poorly differentiated adenocarcinomas (PDAs). The loss of MLH1 due to hypermethylation would lead to microsatellite instability (MSI) status, which promotes carcinogenesis. The loss of SWI/SNF complex family members such as ARID1A would promote a morphological shift as a second hit rather than carcinogenesis. Colorectal medullary carcinoma (MC) is similar to MMR‐deficient solid‐type PDA except for its high frequency of *BRAF* mutation](CAS-111-1008-g005){#cas14301-fig-0005}

In the MMR‐deficient group, we observed the loss of SWI/SNF members (ARID1A, BRG1, BRM, and BAF155) significantly more frequently in solid components compared to glandular components. Only ARID1A loss was associated with favorable prognosis in solid‐type PDAs. As discussed already, the features of colorectal MC are ARID1A loss, MSI, and favorable prognosis. Therefore, ARID1A aberration could play a main role in the morphological shift to these histological types, especially in microsatellite unstable tumors of stomach and colon. In the MMR‐proficient group, we observed the loss of BRG1 significantly more frequently in solid components compared to glandular components, whereas there were no significant differences of other SWI/SNF complex subunits between solid and glandular components. BRG1 might play a main role in the morphological shift in MMR‐proficient solid‐type PDAs.

In the present study, we focused on solid‐type PDA because of its distinct features, such as a favorable prognosis and high frequency of MSI compared to nonsolid‐type PDA.[1](#cas14301-bib-0001){ref-type="ref"}, [6](#cas14301-bib-0006){ref-type="ref"}, [7](#cas14301-bib-0007){ref-type="ref"} Solid‐type PDA seems to correspond to solid carcinoma, which is a poorly differentiated variant of tubular adenocarcinoma in the WHO classification.[38](#cas14301-bib-0038){ref-type="ref"} Solid carcinoma is similar to intestinal‐type GC in molecular features.[39](#cas14301-bib-0039){ref-type="ref"} Nonsolid‐type PDA and signet‐ring cell carcinoma correspond to diffuse‐type GC in Lauren's classification[40](#cas14301-bib-0040){ref-type="ref"} or poorly cohesive carcinoma in the WHO classification.[38](#cas14301-bib-0038){ref-type="ref"}

According to The Cancer Genome Atlas, diffuse‐type morphology is associated with GS, which is one of the molecular subtypes of GC.[9](#cas14301-bib-0009){ref-type="ref"} ARID1A alteration is rarer in GS‐subtype tumors compared to MSI or EBV subtypes.[9](#cas14301-bib-0009){ref-type="ref"} Additionally, nonsolid‐type PDAs and signet‐ring cell carcinomas showed rarer losses of SWI/SNF complex subunits than solid‐type PDAs in the present study. Therefore, the loss of SWI/SNF family members might induce solid morphology rather than some other poorly differentiated histology.

A previous study reported that ARID1A knockdown promotes tumor growth in xenograft models.[22](#cas14301-bib-0022){ref-type="ref"} In this study, solid‐type PDAs showed larger size, more frequent expansive growth, and losses of SWI/SNF family members compared to GC in the control group. However, there were no correlations between the expressions of SWI/SNF complex subunits and cancer depth or cancer stage in solid‐type PDAs. Deficiency in any of the SWI/SNF complex subunits did not correlate with unfavorable prognosis. Although deficiency of the SWI/SNF complex could promote expansive growth, it might not contribute to aggressive behavior in GC.

Regarding heterogeneous expressions of SWI/SNF complex subunits, solid‐type PDAs often showed different expression patterns of each subunit in solid or glandular components, as discussed above. In addition, some cases labeled ''partial loss'' of each subunit showed distinctly separated positive expression and negative expression areas in solid components. Previous studies showed intratumoral heterogeneity of SWI/SNF complex subunits in several tumors.[11](#cas14301-bib-0011){ref-type="ref"}, [22](#cas14301-bib-0022){ref-type="ref"}, [27](#cas14301-bib-0027){ref-type="ref"} Intratumoral heterogeneity will be an important challenge when the SWI/SNF complex becomes a therapeutic target in the future.

Epstein‐Barr virus infection was not frequent (4%) in solid‐type PDAs in this study. It was reported that EBVaGC shows a higher density of TILs than GC with MSI.[41](#cas14301-bib-0041){ref-type="ref"} Epstein‐Barr virus‐associated GC is associated with male sex, upper third location, and lymphoepithelioma‐like histology,[42](#cas14301-bib-0042){ref-type="ref"}, [43](#cas14301-bib-0043){ref-type="ref"}, [44](#cas14301-bib-0044){ref-type="ref"} whereas GC with MSI is associated with female sex and lower third location. The clinicopathological features of EBVaGC thus differ from those of MMR‐deficient solid‐type PDAs.

As for mutational analysis, the frequencies of *BRAF* mutation differ between the gastric solid‐type PDAs in our study (2%) and colorectal MCs. Medullary morphology, MSI, and *BRAF* mutation correlate with each other in colorectal cancer,[25](#cas14301-bib-0025){ref-type="ref"}, [34](#cas14301-bib-0034){ref-type="ref"}, [35](#cas14301-bib-0035){ref-type="ref"}, [36](#cas14301-bib-0036){ref-type="ref"}, [37](#cas14301-bib-0037){ref-type="ref"}, [45](#cas14301-bib-0045){ref-type="ref"} whereas *BRAF* mutation is rare in GC with or without MSI.[9](#cas14301-bib-0009){ref-type="ref"}, [46](#cas14301-bib-0046){ref-type="ref"}, [47](#cas14301-bib-0047){ref-type="ref"} These findings suggest that solid‐type PDAs are not related to carcinogenesis derived from *BRAF* mutation. As for *KRAS* mutation, van Grieken et al described an association between *KRAS* mutation and MSI in GC,[48](#cas14301-bib-0048){ref-type="ref"} and Arai et al reported relatively frequent *KRAS* mutation (14.1%) in solid‐type PDAs. Our finding of a lower *KRAS* mutation rate (5%) is not consistent with these studies. Further examinations of the molecular characteristics of solid‐type PDAs are necessary to address this discrepancy.

The present study has several limitations. First, we did not analyze the MSI status of MMR‐proficient solid‐type PDAs, and MSI analysis failed in several MMR‐deficient solid‐type PDAs because of poor sample DNA qualities. Second, we did not assess DNA methylation or mutational status of SWI/SNF complex subunits such as ARID1A.

In conclusion, solid‐type PDAs showed a frequent loss of MMR proteins and SWI/SNF complex. Our findings also suggest that loss of SWI/SNF complex might induce a morphological shift from differentiated‐type adenocarcinoma to solid‐type PDA as a second hit rather than carcinogenesis.

DISCLOSURE {#cas14301-sec-0017}
==========

The authors declare that there are no conflicts of interest to disclose.

We thank all of the technical staff of the Department of Pathology, Kyushu University for their assistance.
